A multinational pharmaceutical company is seeking novel treatments for autoimmune and fibrotic diseases of the lung. Our client is particularly interested in novel first-in-class or best-in-class therapeutics for their diseases of interest.
Approaches of Interest:
- Diseases of interest include asthma, COPD and idiopathic pulmonary fibrosis
- Open to a range of modalities, including small molecules, biologics, oral peptides, RNA-based therapeutics, antibody-oligonucleotide conjugates and in vivo cell therapies
- All novel pathways for the above indications will...